INTRODUCTION
It is assumed that there is a relationship between patterns of use of any given antibiotic or antibiotic class and extent of bacterial resistance to that antibiotic or class. More specifically, it is believed that as the use of an antibiotic increases over time, resistance to that antibiotic on the part of one or more bacteria will also increase as would rates of infections with antibiotic-resistant pathogens. Research in this area has indeed provided examples of such relationships although they are not predictably present [1, 2] . However, when such 
RESULTS
Little change was observed in susceptibility of P. aeruginosa over the time period of interest with the biggest change being a 12% difference from period 1 to period 4 for aztreonam (Table 1) . Conversely, the utilization of most of the antibiotics increased over time with the greatest change observed for piperacillin/ tazobactam (92% increase), although overall antibiotic utilization change was not statistically significant (Table 1) 
DISCUSSION
It is generally assumed that increased use of an antibiotic or antibiotic class within a healthcare environment will result in rising resistance to However, this strategy is not always successful, as the relationship between extent of use and extent of resistance does not always exist [5, 6] Further, while this strategy may restore susceptibility to a given drug, it may result in rising resistance to other drugs that are used in its stead [7] . In the current analysis, no large changes in susceptibility were detected despite some rather large changes in utilization of individual antibiotics. As examples, susceptibility rates of P. aeruginosa to meropenem and piperacillin/tazobactam remained largely unchanged, despite increases in use of 70 and 92%, respectively, over the 7-year period of observation. Although no apparent cause-and-effect relationships seemed operative, these results might not pertain to other hospitals especially in light of the variation in antibiotic use from one pediatric hospital to the next [8] . The current study must be viewed in light of being a single-center experience with a limited number of tested isolates. All tested isolates were considered and no attempt was made to distinguish those causing infection from those that may have been colonizers. Further, this analysis did not take into account possible effects from changing infection control practices during the period of interest. Lastly, it is also certainly possible that there could be a significant lag time between changes in antibiotic use and changes in resistance rates.
Regardless of these results, it is important that susceptibility rates be diligently monitored in the current age of rapidly rising antibiotic resistance, including in pediatric settings so that emergent resistant problems can be detected and addressed [9] . Results from a fairly recent survey of hospitals caring for pediatric patients were used to construct a national antibiogram for the years 2010 and 2011 [10] . With the exceptions of aztreonam and gentamicin, reported susceptibility rates for isolates of P.
aeruginosa in that report were similar to those in our last period of observation. While such national averages may be helpful in settings where a local antibiogram cannot be prepared, local antibiograms are nonetheless the best resource in guiding empiric prescribing decisions.
CONCLUSION
In summary, the susceptibility of pediatric isolates of P. aeruginosa to a number of antibiotics remained relatively stable over a 7-year period despite major changes in utilization of several of these drugs. Thus, large increases in utilization of at least some antibiotics are not uniformly associated with subsequent changes in bacterial resistance.
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